DB 201
Alternative Names: AAV.201; DB-201; DB-XX1Latest Information Update: 28 Nov 2023
At a glance
- Originator Decibel Therapeutics
- Class Gene therapies; Vestibular disorder therapies
- Mechanism of Action ATOH1 protein expression stimulants; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ear disorders
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for preclinical development in Ear disorders in USA (Injection)
- 25 Sep 2023 Decibel Therapeutics has been acquired by Regeneron Pharmaceuticals
- 30 Jan 2020 Decibel Therapeutics plans to initiate the clinical trial for Ear disorders in 2021 (Decibhel Therapeutics pipeline, January 2020)